Back to News
Market Impact: 0.28
Apimeds Pharmaceuticals Stock Skyrockets Thursday: What's Happening?
Source: benzinga.com
Technology & InnovationCompany Fundamentals
Apimeds Pharmaceuticals US shares surged Thursday after wholly owned subsidiary MindWave Innovations secured a 12-month technology-services agreement with Singapore-based AQUAE Holdings. MindWave will build and operate AQUAEChain, providing a new contracted technology-services engagement, though financial terms were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
APUS0.72
More News
- MindWave forms Bermuda insurance venture with Skalup Capital
- Jensen Huang’s $21 billion net worth in AI rout—Nvidia’s recovery will be ‘capped’ after he admitted affair with alleged Chinese spy
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Key AI chip index just broke its long-term trendline. What history says happens next
- Banks, investors grow wary of AI debt, spooked by market selloff